Association between antiplatelet medication and cerebral microbleeds in stroke-free population
Miao-Xin YU1
Ya-Nan JIA2
Dan-Dan YANG3
Run-Hua ZHANG4
Yong JIANG4
Gui-Tao ZHANG1
Hui-Yu QIAO5
Hua-Lu HAN5
Rui SHEN5
Zi-Han NING5
Xi-Hai ZHAO5
Gai-Fen LIU6
Yong-Jun WANG6
1.Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,Beijing,China2.Department of Neurology,the Third Hospital of Hebei Medical University,Shijiazhuang,China3.Department of Radiology,Beijing Geriatric Hospital,Beijing,China4.Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,Beijing,China;China National Clinical Research Center for Neurological Diseases,Beijing,China5.Center for Biomedical Imaging Research,Department of Biomedical Engineering,Tsinghua University,Beijing,China6.Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,Beijing,China;China National Clinical Research Center for Neurological Diseases,Beijing,China;Beijing Institute of Brain Disorders,Capital Medical University,Beijing,China
摘要：BACKGROUND Cerebral microbleeds (CMBs) may increase the risk of future intracerebral hemorrhage and ischemic stroke. However, It is unclear whether antiplatelet medication is associated with CMBs. This study aimed to investigate the association between antiplatelet medication and CMBs in a community-based stroke-free population. METHODS In this cross-sectional study, stroke-free participants aged 18–85 years were recruited from a community in Beijing, China. Demographic, clinical, and antiplatelet medication data were collected through a questionnaire, and all participants under-went blood tests and brain magnetic resonance imaging at 3.0T. The presence, count, and location of CMBs were evaluated using susceptibility-weighted imaging. The association between antiplatelet medication and the presence of CMBs was analyzed using multivariable logistic regression. The associations between antiplatelet medication and CMBs by location (lobar, deep brain or in-fratentorial, and mixed regions) were also analyzed using multinomial logistic regression. A linear regression analysis was con-ducted to determine the association between antiplatelet medication and the log-transformed number of CMBs. RESULTS Of the 544 participants (mean age: 58.65 ± 13.66 years, 217 males), 119 participants (21.88％) had CMBs, and 64 parti-cipants (11.76％) used antiplatelet medication. Antiplatelet medication was found to be associated with CMBs at any location [odds ratio (OR) = 2.39, 95％ CI: 1.24–4.58] and lobar region (OR = 2.83, 95％ CI: 1.36–5.86), but not with the number of CMBs (β = 0.14, 95％ CI: -0.21–0.48). Among antiplatelet medications, aspirin use was found to be associated with any CMB (OR = 3.17, 95％ CI: 1.49–6.72) and lobar CMBs (OR = 3.61, 95％ CI: 1.57–8.26). CONCLUSIONS Antiplatelet medication was associated with CMBs in stroke-free participants, particularly lobar CMBs. Among antiplatelet medications, aspirin use was associated with any CMB and lobar CMBs. Our findings suggest that it might be essent-ial to optimize the management of antiplatelet medication in the stroke-free population with a higher burden of vascular risk fac-tors to reduce the potential risk of CMBs.
机标关键词：associationpopulationbetweenantiplateletcerebralmedicationmicrobleedsstroke-free
论文发表日期：2022-06-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：9( 409-417 )